Scherber RM - Search Results

1

Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.

Mughal TI, Lion T, Abdel-Wahab O, Mesa R, Scherber RM, Perrotti D, Mauro M, Verstovsek S, Saglio G, Van Etten RA, Kralovics R. Mughal TI, et al. Among authors: scherber rm. Hematol Oncol. 2018 Dec;36(5):740-748. doi: 10.1002/hon.2537. Epub 2018 Aug 3. Hematol Oncol. 2018. PMID: 30074634 Free PMC article. Review.

2

Future therapies for the myeloproliferative neoplasms.

Scherber R, Mesa RA. Scherber R, et al. Curr Hematol Malig Rep. 2011 Mar;6(1):22-7. doi: 10.1007/s11899-010-0068-4. Curr Hematol Malig Rep. 2011. PMID: 21080242 Review.

3

Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms.

Johansson P, Mesa R, Scherber R, Abelsson J, Samuelsson J, Birgegård G, Andréasson B. Johansson P, et al. Leuk Lymphoma. 2012 Mar;53(3):441-4. doi: 10.3109/10428194.2011.619608. Epub 2011 Oct 24. Leuk Lymphoma. 2012. PMID: 21883029

4

Quality of life in MPN comes of age as a therapeutic target.

Scherber RM, Geyer HL, Mesa RA. Scherber RM, et al. Curr Hematol Malig Rep. 2014 Dec;9(4):324-30. doi: 10.1007/s11899-014-0239-9. Curr Hematol Malig Rep. 2014. PMID: 25262210 Review.

5

Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.

Mesa RA, Scherber RM, Geyer HL. Mesa RA, et al. Among authors: scherber rm. Leuk Lymphoma. 2015 Jul;56(7):1989-99. doi: 10.3109/10428194.2014.983098. Epub 2015 Mar 17. Leuk Lymphoma. 2015. PMID: 25644746 Review.

6

Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls.

Anderson LA, James G, Duncombe AS, Mesa R, Scherber R, Dueck AC, de Vocht F, Clarke M, McMullin MF. Anderson LA, et al. Am J Hematol. 2015 Oct;90(10):864-70. doi: 10.1002/ajh.24098. Epub 2015 Sep 10. Am J Hematol. 2015. PMID: 26113113 Free article. Clinical Trial.

7

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.

Geyer HL, Dueck AC, Scherber RM, Mesa RA. Geyer HL, et al. Among authors: scherber rm. Mediators Inflamm. 2015;2015:284706. doi: 10.1155/2015/284706. Epub 2015 Oct 11. Mediators Inflamm. 2015. PMID: 26538823 Free PMC article. Review.

8

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms.

Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, Geyer HL, McCallister A, Cotter M, Van Husen B, Harrison CN, Mesa RA. Scherber RM, et al. Cancer. 2016 Feb 1;122(3):477-85. doi: 10.1002/cncr.29753. Epub 2015 Dec 15. Cancer. 2016. PMID: 26670597 Free article.

9

Survival and new cancers with myeloproliferative neoplasms.

Scherber R, Mesa RA. Scherber R, et al. Lancet Haematol. 2015 Jul;2(7):e272-3. doi: 10.1016/S2352-3026(15)00109-X. Epub 2015 Jun 11. Lancet Haematol. 2015. PMID: 26688382 No abstract available.

10

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.

Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ, Reiter A, Birgegard G, Passamonti F, Senyak Z, Vannucchi AM, Paoli C, Xiao Z, Samuelsson J, Mesa RA. Geyer HL, et al. Among authors: scherber rm. Cancer. 2016 Jun 15;122(12):1888-96. doi: 10.1002/cncr.30013. Epub 2016 Apr 12. Cancer. 2016. PMID: 27070130 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page